This Medical Company Announces Potential Sale of Its IBD Program

First Wave BioPharma Streamlines Clinical Pipeline with Potential Sale of Niclosamide IBD Program.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a significant development for the biopharmaceutical industry, First Wave BioPharma (FWBI) has announced a non-binding term sheet to sell its Niclosamide Inflammatory Bowel Disease (IBD) program. This move c…